PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.580.04 (-0.71%)
5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.60%
Negative revenue growth while STERV.HE stands at 2.82%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.22%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-5.65%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-5.65%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-12.70%
Negative net income growth while STERV.HE stands at 42.06%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12.50%
Negative EPS growth while STERV.HE is at 40.74%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-12.50%
Negative diluted EPS growth while STERV.HE is at 40.74%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.22%
Share reduction while STERV.HE is at 0.01%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.22%
Reduced diluted shares while STERV.HE is at 0.23%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-43.60%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-107.83%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-33.25%
Negative 10Y revenue/share CAGR while STERV.HE stands at 7.64%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-4.04%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-7.42%
Negative 3Y CAGR while STERV.HE stands at 6.88%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-34.52%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-7.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-56.90%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
165.20%
Net income/share CAGR 1.25-1.5x STERV.HE's 148.10%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
62.06%
Below 50% of STERV.HE's 314.14%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
76.98%
Positive short-term CAGR while STERV.HE is negative. John Neff would see a clear advantage in near-term profit trajectory.
27.54%
10Y equity/share CAGR 1.25-1.5x STERV.HE's 23.15%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
56.33%
5Y equity/share CAGR above 1.5x STERV.HE's 24.29%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
20.12%
3Y equity/share CAGR at 75-90% of STERV.HE's 24.61%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.06%
Firm’s AR is declining while STERV.HE shows 2.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
9.98%
We show growth while STERV.HE is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
2.52%
Asset growth at 50-75% of STERV.HE's 3.92%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.16%
Similar to STERV.HE's 4.22%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-5.35%
We’re deleveraging while STERV.HE stands at 1.55%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.04%
SG&A growth of 1.04% while STERV.HE is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.